Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Maryland for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Maryland only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Maryland (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Deepnarayan Tiwarri (NPI 1649217464)

Field	Value
Entity Type	Individual
Organization	Deepnarayan Tiwarri
Address	8926 Woodyard Rd
City	Clinton
State	MD
ZIP	20735
Taxonomy	Hematology & Oncology Physician
NPI Enumerated	June 1, 2006

Payer Source	Total Paid
Medicare	$2.6M
Medicaid	$0

Key Findings

This provider is effectively single‑payer in the claims on file: total Medicare revenue is $2.6M and there is no Medicaid billing on file (none). The absence of Medicaid activity indicates the practice’s revenue and payer negotiations will be driven almost entirely by Medicare and commercial arrangements rather than state Medicaid contracts.

Revenue is highly concentrated in a very small set of codes: the precomputed top 3 Medicare codes account for 65.9% of the provider’s total Medicare revenue, with J9271 alone representing $1.2M (51.5% of Medicare revenue). That concentration signals material dependence on a single high-cost oncology drug for the bulk of billed Medicare dollars.

The code mix is characteristic of an infusion‑focused hematology/oncology practice: large volume of J9271 (pembrolizumab), J0897 (denosumab), and chemotherapy/infusion administration codes such as 96413 and 96365, alongside supportive biologics (J2506, Q5122) and frequent lab monitoring codes (85025, 80053, 82728). This pattern points to a practice model centered on outpatient oncology infusions plus accompanying E/M and lab services.

On competitive standing for its top oncology drug, J9271 ranks #135 of 1841 providers nationally (93th percentile; notably above typical national volume for this code), indicating this provider is a high‑volume distributor of pembrolizumab relative to national peers. Other oncology/supportive drug volumes are also elevated versus peers — for example, J0881 ranks #44 of 1114 (96th percentile; notably above typical national volume) and J2506 ranks #22 of 586 (96th percentile; notably above typical national volume) — reinforcing a strong regional/national presence in select biologics.

E/M utilization is unusually high for established‑patient visits: 99214 appears as a top revenue code with 1.1K claims and $119.5K revenue (4.9% of Medicare revenue) and ranks #9068 of 479517 providers nationally (98th percentile; extreme outlier). This extreme outlier status for a common E/M code suggests above‑typical office visit throughput supporting the infusion business, and it may reflect a sizable chronic-care panel or frequent visit cadence tied to infusion cycles.

Ancillary and supportive care billing is meaningful and consistent with oncology practice needs: significant claims for iron therapies (J1439 and J1437), lab panels (85025, 80053), and growth‑factor products including biosimilars (Q5119, Q5122). These services together indicate routine management of treatment‑related anemia, marrow support, and lab monitoring that accompany cytotoxic and immunotherapy regimens.

The provider’s competitive footprint is mixed: nationally high relative volumes on specific oncology drugs and infusion administration codes mark it as a prominent dispenser of those therapies, while many other codes (several lab and E/M entries) have percentiles described as typical or unremarkable, indicating focused specialty strength rather than broad service dominance. This suggests the practice competes strongly on drug/infusion throughput rather than broad outpatient service breadth.

The NPI shows long tenure in the Medicare program (NPI enumerated 2006-06-01 (~20 years)), implying an established practice history; combined with concentrated Medicare revenue ($2.6M) and no Medicaid activity (none), the entity is likely to be operationally stable but sensitive to utilization or reimbursement changes for its top drugs.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

79 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J9271	Injection, pembrolizumab, 1 mg	29,000	$40	$1.2M
J0897	Injection, denosumab, 1 mg	12,660	$20	$227.9K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	1,100	$110	$119.5K
J0881	Injection, darbepoetin alfa, 1 microgram (non-esrd use)	58,000	$1	$116K
J2506	Injection, pegfilgrastim, excludes biosimilar, 0.5 mg	1,140	$80	$94.6K
J1439	Injection, ferric carboxymaltose, 1 mg	84,750	$1	$84.8K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	620	$130	$77.9K
Q5119	Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg	3,060	$20	$70.4K
99213	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a low level of medical decision making, and/or the…	690	$70	$50.8K
Q5122	Injection, pegfilgrastim-apgf (nyvepria), biosimilar, 0.5 mg	470	$100	$45.9K

Showing 1–10 of 79

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 79 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Maryland Distribution

Deepnarayan Tiwarri — 7 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Maryland

Full comparison — all codes billed, vs. state median

79 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J9271	8	60	15,000	$40	$787.6K
J0897	40	340	3,600	$20	$114.4K
J0881	9	60	30,420	$1	$76.4K
J1437	44	50	2,800	$20	$75.1K
Q5119	2	10	3,000	$20	$74.3K
J3490	21	100	70	$450	$62.1K
J2506	3	30	590	$80	$55.2K
Q5122	4	10	470	$90	$52K
J1439	4	40	30,750	$1	$36.2K
96413	23	230	200	$110	$29.6K

Showing 1–10 of 79

Related Providers

Other providers that share a Tax Identification Number (TIN) with Deepnarayan Tiwarri, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Maryland Oncology Hematology P.A.	MD	Hematology & Oncology Physician	$0	$4.6M
Kashif Ali	MD	Hematology & Oncology Physician	$3.6M	$0
Andrew Mener	MD	Hematology & Oncology Physician	$3.5M	$0
Jason Taksey	MD	Medical Oncology Physician	$3.3M	$0
Frederick Min	MD	Hematology & Oncology Physician	$3.2M	$0
Mohit Narang	MD	Medical Oncology Physician	$3M	$0
Frederick Smith	MD	Medical Oncology Physician	$2.7M	$0
Amr Hegazi	MD	Hematology & Oncology Physician	$2.3M	$0
Edward Lee	MD	Medical Oncology Physician	$1.9M	$0
Ravin Garg	MD	Hematology & Oncology Physician	$1.9M	$0

Nearby Providers

Other providers in the same ZIP code as Deepnarayan Tiwarri, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Fescum Inc	MD	Intellectual and/or Developmental Disabilities Residential Treatment Facility	$0	$36.3M
Medstar Southern Maryland Hospital Center Inc	MD	General Acute Care Hospital	$0	$18.4M
M Medical Group, Inc.	MD	Critical Care Medicine (Internal Medicine) Physician	$0	$11.3M
Patient First Maryland Medical Group PLLC	MD	Family Medicine Physician	$0	$7.6M
Nicholas Demonaco	MD	Hematology & Oncology Physician	$1.7M	$0
Jun Sun	MD	Hematology & Oncology Physician	$1.6M	$0
Rita Gupta	MD	Hematology & Oncology Physician	$1.6M	$0
Jose Mendoza	MD	Hematology & Oncology Physician	$1.4M	$0
Ankit Madan	MD	Hematology & Oncology Physician	$1M	$580
Surgcenter Of Southern Maryland, LLC	MD	Ambulatory Surgical Clinic/Center	$807.5K	$25.5K

Deepnarayan Tiwarri — Billing Profile & Reimbursement Data

Sign up for Deepnarayan Tiwarri — Billing Profile & Reimbursement Data policy alerts

Deepnarayan Tiwarri — Billing Profile & Reimbursement Data

Sign up for Deepnarayan Tiwarri — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References